Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong-ho, Kim, Jae Hyeon, Kim, So Ra, Jin, Heung Yong, Rhee, Eun-Jung, Cho, Young Min, Lee, Byung-Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143300/
https://www.ncbi.nlm.nih.gov/pubmed/27914133
http://dx.doi.org/10.3346/jkms.2017.32.1.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143300/
https://www.ncbi.nlm.nih.gov/pubmed/27914133
http://dx.doi.org/10.3346/jkms.2017.32.1.60

Ejemplares similares